Vol 2, No 4 (2017)
Review article
Published online: 2018-03-30

open access

Page views 2284
Article views/downloads 6968
Get Citation

Connect on Social Media

Connect on Social Media

Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases

Aldona Kubica1, Agata Kosobucka1, Piotr Michalski1, Tomasz Fabiszak2, Mirosława Felsmann3
Medical Research Journal 2017;2(4):115-122.


Introduction: The treatment of acute coronary syndromes, besides coronary interventions, includes pharmaco-therapy and lifestyle changes, which together determine a favourable prognosis. Adherence to treatment is a term describing a patient’s behaviour in respect to the patient’s maintenance of the health care provider’s recommendations. Unfortunately, according to WHO data, adherence to long-term therapies for chronic illnesses in developed countries averages only 50%.

Covered areas: Our study focused on available questionnaires for adherence assessment in everyday practice. A comprehensive search of data bases was conducted using appropriate keywords. Out of an initially identified 2081 citations, 93 articles were considered eligible for further analysis. Eventually, nine adherence scales were identified and reviewed.

Expert opinion: There is no so-called “gold standard survey” allowing accurate assessment of every patient for medication adherence. The use of a specific scale must be justified by its validation in a similar group of patients in well designed and properly conducted studies.

Article available in PDF format

View PDF Download PDF file


  1. Santulli G. Epidemiology of cardiovascular disease in the 21th century: Updated numbers and updated facts. J Cardiovasc Dis July. 2013; 1: 1–2.
  2. World Health Organization: Mortality and global burden of disease. www.who.int/gho/mortality_burden_disease/en/.
  3. Zhao S, Zhao H, Wang L, et al. Education is critical for medication adherence in patients with coronary heart disease. Acta Cardiol. 2015; 70(2): 197–204.
  4. Ortolani P, Solinas E, Guastaroba P, et al. Relevance of gender in patients with acute myocardial infarction undergoing coronary interventions. J Cardiovasc Med (Hagerstown). 2013; 14(6): 421–429.
  5. Kubica A. Broszura - narzędzie edukacji zdrowotnej w kardiologii. Przyczynek do dyskusji o skuteczności profilaktyki wtórnej. Folia Cardiologica Excerpta. 2008; 3: 441.
  6. Kubica A. Współpraca z pacjentem – podstawowy warunek skuteczności terapii w chorobie wieńcowej. Choroby Serca i Naczyń. 2009; 6: 131.
  7. Kubica A. Psychologiczny aspekt zawału serca — niedoceniana zmienna w procesie terapii i rehabilitacji. Folia Cardiologica Excerpta. 2009; 4: 197.
  8. Albert NM. Improving medication adherence in chronic cardiovascular disease. Crit Care Nurse. 2008; 28(5): 54–64; quiz 65.
  9. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008; 117(10): 1261–1268.
  10. Polack J, Jorgenson D, Robertson P. Evaluation of different methods of providing medication-related education to patients following myocardial infarction. Can J Hosp Pharm. 2008; 141(4): 241–247.
  11. Kubica A, Pufal J, Moczulska B, et al. Ocena wiedzy dotyczącej profilaktyki i objawów choroby niedokrwiennej serca u osób hospitalizowanych w klinice kardiologii. Psychiatria w Praktyce Ogólnolekarskiej. 2004; 4: 135.
  12. Kubica A, Pufal J, Moczulska B, et al. Skuteczność edukacji zdrowotnej u osób hospitalizowanych w klinice kardiologii. Psychiatria w Praktyce Ogólnolekarskiej. 2005; 5: 61.
  13. Geest SDe, Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. European Journal of Cardiovascular Nursing. 2016; 2(4): 323–323.
  14. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557): 15.
  15. Kubica J, Adamski P, Buszko K, et al. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2017 [Epub ahead of print].
  16. Winter MP, Grove EL, De Caterina R, et al. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother. 2017; 3(4): 221–234.
  17. Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015; 11(4): 259–280.
  18. Stewart K, Mc Namara KP, George J. Challenges in measuring medication adherence: experiences from a controlled trial. Int J Clin Pharm. 2014; 36(1): 15–19.
  19. Kubica A, Sinkiewicz W, Szymański P, et al. Edukacja zdrowotna w chorobach układu krążenia - możliwości i zagrożenia. Folia Cardiologica Excerpta. 2007; 2: 177.
  20. Kubica A. Wybrane problemy prewencji wtórnej u chorych po incydentach wieńcowych. Folia Cardiologica Excerpta. 2008; 3: 366.
  21. Kubica A, Obońska K, Kasprzak M, et al. The impact of metabolic syndrome on the antiplatelet effect of clopidogrel and aspirin in patients with acute coronary syndrome. : Folia Med Copernicana. 2014; 2: 66–72.
  22. Kubica A, Kasprzak M, Obońska K, et al. Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction. Medical Research Journal. 2016; 3(4): 154–159.
  23. Li WW, Kuo CT, Hwang SL, et al. Factors related to medication non-adherence for patients with hypertension in Taiwan. J Clin Nurs. 2012; 21(13-14): 1816–1824.
  24. Jeffery RA, Navarro T, Wilczynski NL, et al. Adherence measurement and patient recruitment methods are poor in intervention trials to improve patient adherence. J Clin Epidemiol. 2014; 67(10): 1076–1082.
  25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5): 487–497.
  26. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011; 26(3): 155–159.
  27. Kubica A. Problems of long-term antiplatelet therapy after coronary stent implantation. Advances in Interventional Cardiology. 2009; 5: 158–161.
  28. Kubica A, Obońska K, Kasprzak M, et al. The impact of metabolic syndrome on the antiplatelet effect of clopidogrel and aspirin in patients with acute coronary syndrome. Folia Med Copernicana. 2014; 2: 66–72.
  29. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis. 2011; 32(4): 459–466.
  30. Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013.
  31. Vrijens B, De Geest S, Hughes DA, et al. ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5): 691–705.
  32. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015; 2015: 217047.
  33. Kubica A, Grześk G, Sinkiewicz W, et al. Compliance, concordance, adherence in chronic therapy. Folia Cardiol Excerpta. 2010; 5: 54–57.
  34. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009; 3(3): e123–e130.
  35. Cuevas CD, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. International Journal of Clinical and Health Psychology. 2015; 15(2): 121–129.
  36. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1): 67–74.
  37. Muntner P, Joyce C, Holt E, et al. Defining the minimal detectable change in scores on the eight-item Morisky Medication Adherence Scale. Ann Pharmacother. 2011; 45(5): 569–575.
  38. Tan Xi, Patel I, Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). INNOVATIONS in pharmacy. 2014; 5(3).
  39. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003). 2011; 51(1): 90–94.
  40. Afonso N, Nassif G, Aranba A, et al. Low-density lipoprotein cholesterol goal attainment among high- risk patient: does a combine intervention targeting patients and provides work? AM J Mang Care. 2006; 12(10): 589.
  41. George CF, Peveler RC, Heiliger S, et al. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol. 2000; 50(2): 166–171.
  42. Pandey A, Raza F, Velasco A, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens. 2015; 9(6): 420–426.e2.
  43. Marcum ZA, Zheng Y, Perera S, et al. Health ABC Study. Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension. Res Social Adm Pharm. 2013; 9(6): 817–827.
  44. Kripalani S, Schmotzer B, Jacobson TA. Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): a randomized controlled trial. J Gen Intern Med. 2012; 27(12): 1609–1617.
  45. Korb-Savoldelli V, Gillaizeau F, Pouchot J, et al. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens (Greenwich). 2012; 14(7): 429–434.
  46. Unni EJ, Farris KB. Development of a new scale to measure self-reported medication nonadherence. Res Social Adm Pharm. 2015; 11(3): e133–e143.
  47. Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann Pharmacother. 2009; 43(5): 950–957.
  48. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008; 10(5): 348–354.
  49. Saleem F, Hassali MA, Shafie AA, et al. Translation and validation study of Morisky Medication Adherence Scale (MMAS): the Urdu version for facilitating person-centered healthcare in Pakistan. Int J Pers Cent Med. 2012; 2: 384–390.
  50. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas. 2007; 15(3): 203–219.
  51. Rapin P, Yupin A, Sureeporn T, et al. Validity and Reliability of Thai Version of Questionnaire Measuring Self-efficacy for Appropriate Medication Use Scale among Thai with post-myocardial infarction. Songklanakarin J Sci Technol. 2014; 36: 411–417.
  52. Lambert EV, Steyn K, Stender S, et al. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006; 16(1): 286–291.
  53. Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000; 15(3): 90–96.
  54. Song Y, Han HR, Song HJ, et al. Psychometric evaluation of hill-bone medication adherence subscale. Asian Nurs Res (Korean Soc Nurs Sci). 2011; 5(3): 183–188.
  55. Karademir M, Koseoglu IH, Vatansever K, et al. Validity and reliability of the Turkish version of the Hill-Bone compliance to high blood pressure therapy scale for use in primary health care settings. Eur J Gen Pract. 2009; 15(4): 207–211.
  56. Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999; 37(2): 113–124.
  57. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. Rev Saude Publica. 2012; 46(2): 279–289.
  58. Krass I, Taylor SJ, Smith C, et al. Impact on medication use and adherence of Australian pharmacists' diabetes care services. J Am Pharm Assoc (2003). 2005; 45(1): 33–40.
  59. Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007; 3(4): 363–377.
  60. Buszko K, Obońska K, Michalski P, et al. The Adherence Scale in Chronic Diseases (ASCD). The power of knowledge: the key to successful patient — health care provider cooperation. Medical Research Journal. 2016; 1(1): 37–42.
  61. Lucca JM, Ramesh M, Parthasarathi G, et al. Incidence and factors associated with medication nonadherence in patients with mental illness: a cross-sectional study. J Postgrad Med. 2015; 61(4): 251–256.
  62. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53(4): 1020–1024.
  63. Haynes RB, Yao X, Degani A, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews. 2005.
  64. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Preference and Adherence. 2018; Volume 12: 333–340.
  65. Kubica A, Kosobucka A, Michalski P, et al. The Adherence in Chronic Diseases Scale — a new tool to monitor implementation of a treatment plan. Folia Cardiologica 2017;12:19-26, DOI: 10. 5603/FC. ; 2016: 0000.
  66. Ma C, Chen S, You L, et al. Development and psychometric evaluation of the Treatment Adherence Questionnaire for Patients with Hypertension. J Adv Nurs. 2012; 68(6): 1402–1413.
  67. Martin AL, Bayarre Ve. Grau Ábalo JA. Validation of MBG Questionnaire (Martin-Bayarre-Grau) for the evaluation of therapy adherence in blood hypertension patients. Rev Cuba Salud Publica. ; 2008: 34.
  68. Martínez JW, Villa Pe, Jaramillo J. Quintero Betancur AM, Calderón V. Validación del cuestionario de adherencia al tratamiento anti hipertensivo Martín Bayarré Grau. [Validation of a scale of adherence treatment antihypertensive: Martin Bayarre Grau Test]. Rev Med Risaralda. 2011; 17: 101–105.
  69. Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. J Clin Epidemiol. 2008; 61(3): 282–288.
  70. Kubica A, Jurek A, Olejarczyk E, et al. Wybrane czynniki demograficzno-społeczne a skuteczność edukacji zdrowotnej prowadzonej na podstawie broszur edukacyjnych u osób z ostrym zawałem serca. Folia Cardiologica Excerpta. 2008; 3: 199.
  71. Kubica A, Kochman W, Bogdan M, et al. The influence of undergone percutaneous coronary interventions, and earlier hospitalizations with myocardial infarction on the level of knowledge and the effectiveness of health education in patients with myocardial infarction. Advances in Interventional Cardiology. 2009; 5: 25–30.
  72. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004; 42(3): 200–209.
  73. Tang L, Patao C, Chuang J, et al. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). Am J Cardiol. 2013; 112(8): 1126–1132.
  74. Galema-Boers JMH, Lenzen MJ, van Domburg RT, et al. Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2014; 70(4): 391–397.
  75. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006; 113(24): 2803–2809.
  76. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
  77. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  78. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
  79. Muntner P, Mann DM, Woodward M, et al. Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol. 2011; 108(6): 822–827.
  80. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
  81. Vitolins MZ, Rand CS, Rapp SR, et al. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000; 21(5 Suppl): 188S–94S.
  82. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004; 42(7): 649–652.
  83. Cook CL, Wade WE, Martin BC, et al. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc (2003). 2005; 45(2): 151–159.
  84. Wang PS, Benner JS, Glynn RJ, et al. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004; 13(1): 11–19.
  85. Frost MH, Reeve BB, Liepa AM, et al. Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group;. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007; 10 Suppl 2: S94–S9S105.
  86. Krousel-Wood M, Muntner P, Jannu A, et al. Reliability of a medication adherence measure in an outpatient setting. Am J Med Sci. 2005; 330(3): 128–133.
  87. Kubica A. Collaboration with the patient - a basic condition of therapy effectiveness in coronary artery disease. Chor. Serca Nacz. 2009; 6: 131–134.
  88. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999; 21(6): 1074–90; discussion 1073.
  89. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119(23): 3028–3035.
  90. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166(17): 1842–1847.
  91. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001; 26(5): 331–342.
  92. Shi L, Liu J, Fonseca V, et al. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010; 8: 99.
  93. Pérez-Escamilla B, Franco-Trigo L, Moullin JC, et al. Identification of validated questionnaires to measure adherence to pharmacological antihypertensive treatments. Patient Prefer Adherence. 2015; 9: 569–578.